SGIOF:OTCMKTS
Shionogi & Co Ltd
19,10 USD
0,00%
(0,00) 1d
17 d’abr., 15:56:59 GMT-4 · USD
search
Tots els símbols
1d
5d
1m
6m
YTD
1a
5a
Màx.
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a SGIOF...
Capitalització borsària
2,78 B
Volum mitjà
73,00
Volum
0,00
Alt 52 setmanes
26,00 USD
Baix 52 setmanes
14,25 USD
Versió beta
-0,83
Accions en circulació
889,63 M
Nombre d'empleats
5 k
Notícies
De fonts en tot el web
Investor's Business Daily
·
fa 38 minuts
Dow Jones Futures Rise; Trump Says U.S. To 'Guide' Ships Through Hormuz
Yardeni QuickTakes
·
fa 49 minuts
MARKET CALL: Up, Up & Away
Perfil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Sobre Shionogi & Co Ltd
Conseller delegatIsao Teshirogi
Empleats4,96 k
Fundació1878
Seu principalOsaka, Prefectura d'Osaka, Japó
Sector-
Lloc webshionogi.com
El contingut d'IA pot incloure errors. Més informació